Bristol-Myers Squibb
BMY
58.80
+0.46
+0.79%
Bristol-Myers Squibb
US · BMY
#158 by market cap
Listed 1970
58.80
+0.46
+0.79%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/11/16
-
New drug portfolio drives growth; Bristol-Myers Squibb (BMY.US) Q3 results beat expectationsZhitong Finance · 2026/10/29
-
Rating change
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $41 to $80Market Newswire · 2026/10/8
-
Rating change
UBS Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $80Market Newswire · 2026/8/20
-
RBC Capital Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $64Market Newswire · 2026/10/28
-
Rating change
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $63Market Newswire · 2026/10/13
-
Rating change
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold RatingMarket Newswire · 2026/8/21
-
Rating change
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $41 to $82Market Newswire · 2026/10/13
-
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $64 to $75Market Newswire · 2026/10/30
-
Rating change
Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Cuts Target Price to $78Market Newswire · 2026/10/26
-
Rating change
HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $65Market Newswire · 2026/9/10
-
Rating change
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $66 to $82Market Newswire · 2026/10/10
-
Rating change
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $65Market Newswire · 2026/9/30
-
Rating change
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $63Market Newswire · 2026/10/20
-
Rating change
Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/10/27
-
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $40Market Newswire · 2026/10/30
-
Rating change
Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $82Market Newswire · 2026/9/16
-
Rating change
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $60 to $82Market Newswire · 2026/10/9
-
Rating change
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $40Market Newswire · 2026/9/25
-
Rating change
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Raises Target Price to $41Market Newswire · 2026/10/7
-
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/10/29
-
Rating change
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $70Market Newswire · 2026/8/14
-
Rating change
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/8/12
-
Rating change
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $73Market Newswire · 2026/8/5
-
Rating change
Argus Research Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Announces Target Price $75Market Newswire · 2026/8/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments